About Liquid Genomics
Liquid Genomics is a Healthcare company based in Torrance (United States) founded in 2013, and was acquired by NantHealth in February 2018. Blood-based molecular diagnostics for cancer are developed and offered. Liquid Genomics has raised $4.86 million across 3 funding rounds from investors including NantHealth. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its competitors include GRAIL, Color and Earli; 3 of its 3 listed competitors have raised funding.
Company details
Liquid Genomics offers blood-based molecular diagnostics for cancer. Its flagship product analyzes bloods samples for circulating tumor DNA and RNA using PCR to monitor efficacy of chemotherapy treatments and risk of cancer recurrence. Current markers tested are variants of EGFR, ALK, KRAS, BRAF, NRAS, PD-L1, AR-V7 and ROS1.
- Headquarters Torrance, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website liquidgenomics.com
- Social X
- Acquired by NantHealth (Feb 2018)
- Total Equity Funding$4.86M (USD)
in 3 rounds
- Latest Funding Round$1.63M (USD), Series A
Jan 2017
- Investors
- Acquired byNantHealth
(Feb 2018)
Funding Insights of Liquid Genomics
Liquid Genomics has successfully raised a total of $4.86M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.63 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.86M
- Total Rounds 3
- Last Round Series A β $1.63M
All 3 funding rounds of Liquid Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $1.63M | Series A | β | β | β |
| May 2014 | $3.24M | Series A | β | β | β |
| May 2014 | Debt – Conventional | β | β | β |
1 investors in total: 1 institutional.
Investors in Liquid Genomics
Liquid Genomics has secured backing from 1 investor. Prominent investors backing the company include NantHealth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Bioinformatics platforms are provided for cancer treatment identification. | 2007 | nanthealth.com | El Segundo, United States |
Investor details for Liquid Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Liquid Genomics
4 dated milestones of Liquid Genomics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Liquid Genomics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $1.6M.
- Exit Acquired by NantHealth.
Competitors of Liquid Genomics
Liquid Genomics has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Color and Earli.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| earli.com | 2018 | San Francisco, United States | $40M | 38 | Early cancer detection tests are developed using synthetic biomarkers. |
Detailed competitors of Liquid Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Liquid Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Liquid Genomics
Liquid Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Liquid Genomics is headquartered in Torrance, United States. It is registered at Torrance, California, United States.
Liquid Genomics is a funded company, having raised a total of $4.86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.24M, raised on May 2014.
Liquid Genomics offers blood-based molecular diagnostics for cancer. Its flagship product analyzes bloods samples for circulating tumor DNA and RNA using PCR to monitor efficacy of chemotherapy treatments and risk of cancer recurrence. Current markers tested are variants of EGFR, ALK, KRAS, BRAF, NRAS, PD-L1, AR-V7 and ROS1.
Liquid Genomics has 1 investor. Key investors include NantHealth.
Yes. Liquid Genomics was acquired by NantHealth in February 2018.
